Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Clene Inc (CLNN)

Clene Inc (CLNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights GlobeNewswire - Thu Mar 12, 7:00AM CDT

In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026...

CLNN : 4.71 (-12.62%)
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts GlobeNewswire - Tue Feb 24, 7:00AM CST

Operating capital runway sufficient into the fourth quarter of 2026  In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late...

CLNN : 4.71 (-12.62%)
Clene to Present at the Emerging Growth Conference GlobeNewswire - Thu Feb 19, 7:30AM CST

SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical...

CLNN : 4.71 (-12.62%)
Clene to Present at the Emerging Growth Conference GlobeNewswire - Fri Jan 16, 7:30AM CST

SALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical...

CLNN : 4.71 (-12.62%)
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting GlobeNewswire - Mon Jan 12, 7:30AM CST

The FDA has granted an in-person Type C meeting during the first quarter of 2026  New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly...

CLNN : 4.71 (-12.62%)
Clene Announces Registered Direct Offering of Over $28 Million GlobeNewswire - Fri Jan 9, 7:30AM CST

Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo Capital Initial financing tranche...

CLNN : 4.71 (-12.62%)
Clene to Present at the Emerging Growth Conference GlobeNewswire - Tue Dec 9, 2025

SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical...

CLNN : 4.71 (-12.62%)
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8® GlobeNewswire - Wed Dec 3, 2025

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 Biomarker improvements are strongly associated with longer survival,...

CLNN : 4.71 (-12.62%)
Clene to Provide CNM-Au8® ALS Program Update GlobeNewswire - Tue Dec 2, 2025

SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical...

CLNN : 4.71 (-12.62%)
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference GlobeNewswire - Thu Nov 20, 2025

SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical...

CLNN : 4.71 (-12.62%)

Barchart Exclusives

Stocks Set to Open Higher as Bond Yields Fall on Fading Rate-Hike Bets, U.S. Jobs Data and Powell’s Remarks Awaited Barchart - 12 minutes ago
June S&P 500 E-Mini futures (ESM26) are up +0.38%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.39% this morning, pointing to a higher open on Wall Street as Treasury yields retreated, while investors continued to monitor developments in the Middle East. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.